ALLMedicine™ Acute Megakaryoblastic Leukemia Center
Research & Reviews 101 results
The Journal of Clinical Investigation; Evans EJ, DeGregori J
Jul 16th, 2022 - Individuals with Down syndrome (DS) have more than 100-fold increased risk of acute megakaryoblastic leukemia (AMKL), but its pathogenesis is poorly understood. In this issue of the JCI, Arkoun et al. engineered stepwise DS-AMKL-associated mutatio...
The Journal of Clinical Investigation; Arkoun B, Robert E et. al.
May 20th, 2022 - Acute megakaryoblastic leukemia of Down syndrome (DS-AMKL) is a model of clonal evolution from a preleukemic transient myeloproliferative disorder requiring both a trisomy 21 (T21) and a GATA1s mutation to a leukemia driven by additional driver mu...
Genes, Chromosomes & Cancer; Gillam J, Catic A et. al.
Mar 17th, 2022 - Non-Down-syndrome-related acute megakaryoblastic leukemia (non-DS-AMKL) is a rare form of leukemia that can present with a variety of initial symptoms, including fever, rash, bruising, bleeding, or other more clinically challenging symptoms. Herei...
Blood Hasle H, Kline RM et. al.
Nov 11th, 2021 - Individuals with Down syndrome are at increased risk of myeloid leukemia in early childhood, which is associated with acquisition of GATA1 mutations that generate a short GATA1 isoform called GATA1s. Germline GATA1s-generating mutations result in ...
Blood Alejo-Valle O, Weigert K et. al.
Sep 28th, 2021 - Given the plasticity of hematopoietic stem and progenitor cells, multiple routes of differentiation must be blocked in the the pathogenesis of acute myeloid leukemia, the molecular basis of which is incompletely understood. We report that posttran...
Clinicaltrials.gov 5 results
May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...
May 17th, 2017 - OBJECTIVES: To perform high throughput sequencing of a set of megakaryocyte specific transcription factors, tyrosine kinases, and Src kinases in DNA isolated from bone marrow specimens of adults with acute megakaryoblastic leukemia (AMKL). To assa...
May 18th, 2016 - Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved mRNA Study Population Description: Samples from AAML0531 Sampling...
Feb 23rd, 2016 - OBJECTIVES: Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Do...
Feb 16th, 2015 - This is an open-label, multi-center, 10 patient pilot study with an anticipated 1 year enrollment period Primary Objectives: To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and ida...
News 2 results
Jan 24th, 2017 - Micrograph showing AMKL Image courtesy of St. Jude Children’s Research Hospital and Tina Motroni Research has revealed genetic alterations that may prove useful for predicting treatment outcomes in pediatric patients with acute megakaryoblastic le.
Jan 13th, 2016 - Megakaryocytes in the bone marrow Investigators have discovered a new mechanism of megakaryocyte differentiation, according to a paper published in eLife. They found that overexpression of the methyltransferase enzyme PRMT1 in acute megakaryocytic.